Management of highly sensitized patients: capitol medical center experience.
Highly sensitized patients with elevated anti-HLA antibodies have difficulty to get a living donor due to cross-match positivity and longer waiting times for cadaveric donor transplantation. In this regard, several studies have been made to abrogate cross-match positivity for a possible successful kidney transplantation. In this article, we report our experience, using a desensitization protocol with Rituximab monoclonal antibody complemented with intravenous immunoglubulin and/or plasmapheresis, to prepare highly sensitized patients for successful kidney transplantation.
Amante
A J
AJ
Capitol Medical Center, Quezon City, Philippines.
Ejercito
R
R
D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D058846:Antibodies, Monoclonal, Murine-Derived; D003404:Creatinine / Q000097:blood; D005260:Female; D006680:HLA Antigens / Q000276:immunology*; D006650:Histocompatibility Testing; D006801:Humans; D006967:Hypersensitivity / Q000276:immunology*; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use; D007155:Immunologic Factors / Q000627:therapeutic use; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007518:Isoantibodies / Q000276:immunology; D016030:Kidney Transplantation / Q000276:immunology*; D019520:Living Donors; D008297:Male; D008875:Middle Aged; D010956:Plasmapheresis; D000069283:Rituximab
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D006680:HLA Antigens; D016756:Immunoglobulins, Intravenous; D007155:Immunologic Factors; D007166:Immunosuppressive Agents; D007518:Isoantibodies; D000069283:Rituximab; D003404:Creatinine